NCT05067946View on ClinicalTrials.gov

Evaluation of Efficacy, Safety and Immunogenicity of GX-19N in Healthy Individuals Who Have Received COVID-19 Vaccines

PHASE2/PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

October 31, 2021

Primary Completion Date

October 31, 2022

Study Completion Date

October 31, 2023

Conditions
SARS-CoV2 Infection
Interventions
BIOLOGICAL

GX-19N

DNA vaccine expressing SARS-CoV-2 S-protein antigen including the Nucleocapsid protein (NP) antigen

OTHER

Placebo

GX-19N formulation buffer

Sponsors

Lead Sponsor

Genexine, Inc.
All Listed Sponsors
collaborator

PT Kalbe Farma Tbk

INDUSTRY

lead

Genexine, Inc.

INDUSTRY

NCT05067946 - Evaluation of Efficacy, Safety and Immunogenicity of GX-19N in Healthy Individuals Who Have Received COVID-19 Vaccines | Biotech Hunter | Biotech Hunter